COMPASS PATHWAYS PLC -

COMPASS Pathways plc to announce second quarter 2022 financial results on 4 August 2022

26 Jul 2022 07:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways appoints Kabir Nath as Chief Executive Officer

19 Jul 2022 07:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting

23 May 2022 06:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways to participate in upcoming Citi’s Biopharma Virtual Co-Panel Day and H.C. Wainwright Global Investment Conference

12 May 2022 07:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways plc announces first quarter 2022 financial results and business highlights

10 May 2022 06:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults

09 May 2022 06:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways plc to announce first quarter 2022 financial results on 10 May 2022

03 May 2022 07:00:00 By Nasdaq GlobeNewswire

COMP360 psilocybin therapy shows potential in exploratory open-label studies for anorexia nervosa and severe treatment-resistant depression

03 May 2022 06:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways partners with One Mind to fund Rising Star Awards for the next generation of mental health researchers

20 Apr 2022 06:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways to participate in Needham Healthcare conference

04 Apr 2022 07:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways and partners launch The Centre for Mental Health Research and Innovation, in the UK

24 Mar 2022 04:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways to participate in Cowen and Roth investor conferences

02 Mar 2022 06:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways announces financial results for the fourth quarter and full year 2021 and business highlights

24 Feb 2022 06:12:48 By Nasdaq GlobeNewswire

COMPASS Pathways plc to announce fourth quarter and full year 2021 financial results on 24 February 2022

17 Feb 2022 11:20:59 By Nasdaq GlobeNewswire

Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression

19 Jan 2022 06:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways to participate in H.C. Wainwright investor conference

10 Jan 2022 06:00:00 By Nasdaq GlobeNewswire

COMP360 psilocybin study of 89 healthy participants published in Journal of Psychopharmacology

04 Jan 2022 06:00:00 By Nasdaq GlobeNewswire

COMPASS Selected for Addition to NASDAQ Biotechnology Index

17 Dec 2021 06:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways announces changes in Executive Team

16 Dec 2021 06:40:00 By Nasdaq GlobeNewswire

COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study

13 Dec 2021 06:00:02 By Nasdaq GlobeNewswire